News

Alopecia and nausea risk may be more easily identified in patients initiating methotrexate for rheumatoid arthritis.

A study presented at ACR 2021 found that CBD had no significant effect on pain intensity in patients with hand osteoarthritis or psoriatic arthritis.

Year-long treatment with the biologic resulted in significant improvements in patient perception of well-being and treatment effect.

An assessment of data from the DISCOVER and VOYAGE trials show the IL-23 inhibitor provides similar safety profiles in patients with either psoriatic disease.

Investigators reported that the medication was safe for patients with moderate-to-severe atopic dermatitis regardless of the presence of allergic comorbidities.

Interim data from a post-marketing analysis suggest a boxed label warning for the drug in 2019 may have limited high-risk patients taking the biologic therapy.

A cross-sectional analysis suggests patients with worse social risk scores are significantly more likely to be impacted by juvenile idiopathic arthritis.

This study shows that many patients with rheumatoid arthritis can use a dose lower than 1000mg and still see results.

With the popularity of CBD growing in Denmark, Jonathan Vela, MD, examined the effectiveness of CBD treatment on hand osteoarthritis and psoriatic arthritis.

More data from ACR 2021 evidences the risk of minimal response to mRNA vaccines in autoimmune disorder patients on rituximab.

In this video interview, Dr. Jing Cui explains what the next steps could be for the risk prediction models of systemic lupus erythematosus.

In this video interview, Dr. Edigin talks about the importance of outpatient care in reducing hospitalizations for SLE flare.

Nathan den Broeder, MSs, shares the findings of his study at the ACR 2021 Convergence.

Research presented by Dr. Jing Cui at ACR 2021 Convergence identified significant risk factors for systemic lupus erythematosus in a risk prediction model study.

Research results shows that while overall hospitalization for SLE flare decreased, it increased among African American patients.

Dr. Jing Cui speaks about how she examined lifestyle and environmental factors as well as genetic risk to assess risk of systemic lupus erythematosus.

The oral selective inhibitor showed significant benefit versus placebo at 2 different doses in the phase 2b trial.

A new ACR 2021 study suggests patients on the biologic may be less likely to discontinue treatment than those receiving other drug classes.

New phase 3 data show TX-102 SL from Tonix may benefit central sensitization in patients afflicted with fibromyalgia pain.

A pandemic-era study suggests rheumatology care teams can capably provide beneficial care via telemedicine to treatment-stable patients.

New ACR findings suggest patients taking the common biologic drug closely leading up to their vaccination may not have a humoral response to it.

In this interview, Dr. Edigin speaks about his longitudinal trend analysis that showed a decrease in SLE flare hospitalizations over the last 20 years.

Data show reduction in systolic BP was considered greater than safety concerns related to drugs and interventional treatment, and preference for no intervention over intervention.

Investigators collected data from 5 focus groups of community-based pediatricians to address ongoing concerns on the treatment of atopic dermatitis in this pediatric population.

The randomized control trial investigates the effectiveness of cognitive behavioral therapy in treating chronic pain in patients who have been using opioid therapy.

The adjusted change in 24-hour systolic blood pressure was -11.0 mm Hg in the chlorthalidone group and -0.5 mm Hg in the placebo group.

Data from the LIBERTY AD ADOL trial showed that adolescent patients with moderate-to-severe atopic dermatitis treated with the biologic reported decreases in total and allergen-specific IgE levels for cat dander, peanuts, and more.

Few studies have focused on the psychosocial adjustments of siblings of children with ADHD.

Over half of all patients in the study had achieved an EASI-75 within a year, and investigators noted that patient and family satisfaction with the MADP program was high.

Investigators report that the skin condition mediated the association between a a interleukin-4 receptor agonist variant and food allergy.